Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, USA.
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):490-7. doi: 10.1016/j.clml.2011.06.015. Epub 2011 Sep 1.
It was demonstrated that metallopanstimulin-1 (MPS-1, RPS27) inhibited the growth of tumors formed by head and neck squamous cell carcinoma cells and reduced paxillin gene expression.
The present study examined whether and how MPS-1 affects another type of cancer, multiple myeloma (CAG). Enhanced expression of MPS-1 dramatically inhibited CAG in vitro and in vivo.
Overexpression of MPS-1 resulted in decreased fibroblast growth factor (FGF2) receptor 3 and impaired endogenous MAPK/ErK signaling. MAPK/ErK signaling was not stimulated by adding recombinant FGF2 to myeloma cells overexpressing MPS-1.
These data suggest that MPS-1 suppresses CAG growth and that weakened FGF2 signaling may contribute to this effect.
研究表明金属帕斯蒂姆ulin-1（MPS-1，RPS27）可抑制头颈部鳞状细胞癌细胞形成的肿瘤生长，并降低整联蛋白基因表达。
本研究探讨了 MPS-1 是否以及如何影响另一种癌症，多发性骨髓瘤（CAG）。MPS-1 的过表达显著抑制了体外和体内的 CAG。
MPS-1 的过表达导致成纤维细胞生长因子（FGF2）受体 3 的减少和内源性 MAPK/ErK 信号的损害。向过表达 MPS-1 的骨髓瘤细胞中添加重组 FGF2 不会刺激 MAPK/ErK 信号。
这些数据表明 MPS-1 抑制 CAG 生长，而减弱的 FGF2 信号可能对此作用有贡献。
